Emerging immune checkpoints for cancer therapy.

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Immune checkpoint inhibitors (ICIs) like anti-CTLA-4 and anti-PD-1/PD-L1 antibodies have revolutionized cancer treatment.
• Lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) are emerging immune checkpoints with significant therapeutic potential.
• Understanding the roles of LAG-3 and TIM-3 is critical for advancing cancer immunotherapy strategies.

Purpose of the Study:

• To review the current understanding of LAG-3 and TIM-3 functions in cancer.
• To explore the therapeutic applications of targeting LAG-3 and TIM-3 in cancer immunotherapy.
• To evaluate the potential of combining LAG-3 and TIM-3 inhibition with existing treatments.

Main Methods:

• Comprehensive literature search and data collection from Medline/PubMed.
• Analysis of studies investigating the molecular mechanisms of LAG-3 and TIM-3.
• Review of clinical trial data on agents targeting LAG-3 and TIM-3.

Main Results:

• LAG-3, a CD4 homolog, negatively regulates T cell responses and binds MHC class II molecules. IMP321, a LAG-3-based fusion protein, demonstrated enhanced T cell responses and tolerability in Phase I trials.
• TIM-3 negatively regulates Th1 immunity, and its pathway contributes to a suppressive tumor microenvironment, with overexpression linked to poor prognosis.
• Both LAG-3 and TIM-3 are coexpressed with other immune checkpoints, suggesting combination therapies may improve anti-tumor efficacy.

Conclusions:

• LAG-3 and TIM-3 play critical roles in cancer development and immune evasion.
• Targeting LAG-3 and TIM-3 represents a promising avenue for future cancer immunotherapy clinical practice.
• Combination strategies involving LAG-3 and TIM-3 inhibitors may offer enhanced therapeutic benefits.